{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:41:40Z","timestamp":1774280500598,"version":"3.50.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,24]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pneumocystis pneumonia (PCP) is an opportunistic fungal infection that occurs in people with impaired or suppressed immunity such as patients with human immunodeficiency virus or organ transplant. However, the incidence and characteristics of PCP in the population with long-term hemodialysis is poorly described in the literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present a case of a 50-year-old female patient being transferred to our hospital in February 2022 with a 20-day history of cough and tight breath. She received amoxicillin and cephalosporin anti-infection treatment successively in local hospital but no significant improvement in symptoms. She had a 2-year history of hemodialysis and no relevant transplantation and human immunodeficiency virus infection. She was diagnosed as ANCA associated vasculitis (AAV) and given oral prednisone acetate (20\u2009mg\/day) and methotrexate (2.5\u2009mg\/week) half a year ago.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Based on the patient\u2019s medical history, Lung computerized tomography image, the Next generation sequencing report, the patient was diagnosed with renal failure, anti-neutrophil cytoplasmic antibody associated vasculitis, and Pneumocystis pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The dosage of immunosuppressant was reduced due to leucocyte dripping and fever, and antibiotic and antifungal treatment were also given. The patient\u2019s lung condition was getting worse and noninvasive ventilator was required to maintain blood oxygen. Blood filtration is used to remove toxins. Ganciclovir and trimethoprim-sulfamethoxazole was used based on the next generation sequencing report.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient died of respiratory failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The risk of PCP in hemodialysis patients may be higher than that in ordinary population, and the prognosis of patients with immunosuppression may be worse. Dynamic assessment of vasculitis activity is necessary for hemodialysis patients with AAV because infections may obscure lung symptoms of AAV. It is not recommended that hemodialysis patients with long-term immunosuppression should reduce or stop the dosage of immunosuppressive drugs during the treatment because it may aggravate the condition of PCP. There is still no clear conclusion on whether hemodialysis patients need preventive medicine, but the identification of risk factors and early diagnosis and treatment are important for the prognosis of PCP on hemodialysis population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033351","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T13:04:37Z","timestamp":1679663077000},"page":"e33351","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Case report: A HIV-negative hemodialysis patient positive for pANCA with severe pneumocystis pneumonia: A case report and review of literature"],"prefix":"10.1097","volume":"102","author":[{"given":"Jingda","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic, The First Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meirong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8933","authenticated-orcid":false,"given":"Dehui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ganzhou People\u2019s Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mayocp.2020.07.029","article-title":"Host factors and outcomes in hospitalizations for pneumocystis jirovecii pneumonia in the United States.","volume":"96","author":"Kanj","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/14656566.2021.1915989","article-title":"Pneumocystis jirovecii: a review with a focus on prevention and treatment.","volume":"22","author":"Weyant","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients.","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.3390\/ijms21103422","article-title":"Molecular mechanisms of premature aging in hemodialysis: the complex interplay between innate and adaptive immune dysfunction.","volume":"21","author":"Losappio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3109\/00365548.2014.936492","article-title":"Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population.","volume":"46","author":"Leth","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6413-3-22","article-title":"Alveolar proteinosis in a patient recovering from pneumocystis carinii infection: a case report with a review of literature.","volume":"3","author":"Kotov","year":"2006","journal-title":"Cytojournal"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP69130","article-title":"Type B insulin resistance syndrome induced by increased activity of systemic lupus erythematosus in a hemodialysis patient.","volume":"69","author":"Nagayama","year":"2008","journal-title":"Clin Nephrol"},{"key":"R8-20250504","first-page":"384","article-title":"A case of Goodpasture syndrome positive for anti-GBM antibody and MPO-ANCA complicated by a variety of serious infections.","volume":"75","author":"Sakoda","year":"2011","journal-title":"Clin Nephrol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2369-15-28","article-title":"A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.","volume":"15","author":"Ernst","year":"2014","journal-title":"BMC Nephrol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2214-109X(15)00215-6","article-title":"Mortality and its risk factors in Malawian children admitted to hospital with clinical pneumonia, 2001-12: a retrospective observational study.","volume":"4","author":"Lazzerini","year":"2016","journal-title":"Lancet Glob Health"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1183\/09031936.00155813","article-title":"Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.","volume":"43","author":"Cilloniz","year":"2014","journal-title":"Eur Respir J"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00134-017-4947-1","article-title":"Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.","volume":"43","author":"Azoulay","year":"2017","journal-title":"Intensive Care Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/CMR.00013-12","article-title":"Colonization by pneumocystis jirovecii and its role in disease.","volume":"25","author":"Morris","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199001183220304","article-title":"The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.","volume":"322","author":"Phair","year":"1990","journal-title":"N Engl J Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4 + T-lymphocyte counts during pneumocystis carinii pneumonia in immunocompromised patients without HIV infection.","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1086\/315487","article-title":"Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii.","volume":"181","author":"Shellito","year":"2000","journal-title":"J Infect Dis"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.","volume":"176","author":"Lund","year":"2006","journal-title":"J Immunol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3960\/jslrt.50.159","article-title":"Two cases of pneumocystis jiroveci pneumonia with non-Hodgkin\u2019s lymphoma after CHOP-based chemotherapy containing rituximab.","volume":"50","author":"Kurokawa","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.20279","article-title":"Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener\u2019s granulomatosis.","volume":"62","author":"Hugle","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/ajkd.2001.26092","article-title":"Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients.","volume":"38","author":"Libetta","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-4933-9-19","article-title":"Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients.","volume":"9","author":"Meijers","year":"2012","journal-title":"Immun Ageing"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.jrn.2011.10.020","article-title":"Effect of uremia on structure and function of immune system.","volume":"22","author":"Vaziri","year":"2012","journal-title":"J Ren Nutr"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000276764","article-title":"Leukocyte toll-like receptor expression in end-stage kidney disease.","volume":"31","author":"Gollapudi","year":"2010","journal-title":"Am J Nephrol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1046\/j.1523-1755.2001.59780195.x","article-title":"Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone.","volume":"78","author":"Massry","year":"2001","journal-title":"Kidney Int Suppl"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000168284","article-title":"Impaired phagocytosis in dialysis patients: studies on mechanisms.","volume":"11","author":"Alexiewicz","year":"1991","journal-title":"Am J Nephrol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ndt\/15.4.502","article-title":"B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2.","volume":"15","author":"Fern\u00e1ndez-Fresnedo","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ndt\/gfp397","article-title":"Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression.","volume":"25","author":"Pahl","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20250504","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases.","volume":"21","author":"Godeau","year":"1994","journal-title":"J Rheumatol"},{"issue":"3 Pt 1","key":"R29-20250504","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis.","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3349\/ymj.2019.60.5.454","article-title":"Comparison of radiological and histological findings of lung parenchyma in patients with antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"60","author":"Park","year":"2019","journal-title":"Yonsei Med J"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ejrad.2011.02.052","article-title":"HRCT-features of pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients.","volume":"81","author":"Vogel","year":"2012","journal-title":"Eur J Radiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3).","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","article-title":"A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis.","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2002.03419.x","article-title":"Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years\u2019 experience of infection in GIMEMA centres.","volume":"117","author":"Pagano","year":"2002","journal-title":"Br J Haematol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archpedi.1984.02140490051012","article-title":"Treatment of pneumocystis carinii pneumonitis. A comparative trial of sulfamethoxazole-trimethoprim v pentamidine in pediatric patients with cancer: report from the children\u2019s cancer study group.","volume":"138","author":"Siegel","year":"1984","journal-title":"Am J Dis Child"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028016650107","article-title":"Pneumocystis jirovecii pneumonia in the non-hiv-infected population.","volume":"50","author":"Avino","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0140-6736(87)92219-7","article-title":"Corticosteroids as adjunctive therapy in treatment of pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.","volume":"1","author":"MacFadden","year":"1987","journal-title":"Lancet"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJM199011223232104","article-title":"A controlled trial of early adjunctive treatment with corticosteroids for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California collaborative treatment Group.","volume":"323","author":"Bozzette","year":"1990","journal-title":"N Engl J Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM199011223232103","article-title":"Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.","volume":"323","author":"Gagnon","year":"1990","journal-title":"N Engl J Med"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1378\/chest.102.3.892","article-title":"Corticosteroids for pneumocystis carinii pneumonia with acute respiratory failure. Experience with rescue therapy.","volume":"102","author":"LaRocco","year":"1992","journal-title":"Chest"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1378\/chest.114.5.1258","article-title":"The effect of adjunctive corticosteroids for the treatment of pneumocystis carinii pneumonia on mortality and subsequent complications.","volume":"114","author":"Gallant","year":"1998","journal-title":"Chest"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/598651","article-title":"Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients.","volume":"29","author":"Delclaux","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1128\/AAC.00669-11","article-title":"Outcomes of moderate-to-severe pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients.","volume":"55","author":"Moon","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chest.2018.04.026","article-title":"Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome.","volume":"154","author":"Wieruszewski","year":"2018","journal-title":"Chest"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"e0250611","DOI":"10.1371\/journal.pone.0250611","article-title":"Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with pneumocystis jirovecii pneumonia: a propensity score analysis.","volume":"16","author":"Assal","year":"2021","journal-title":"PLoS One"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.arbres.2016.06.016","article-title":"Adjunctive Corticosteroids for pneumocystis jirovecii pneumonia in non-HIV-infected patients: a systematic review and meta-analysis of observational studies.","volume":"53","author":"Fujikura","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1378\/chest.113.5.1215","article-title":"Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.","volume":"113","author":"Pareja","year":"1998","journal-title":"Chest"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijid.2018.12.001","article-title":"Adjunctive Corticosteroids decreased the risk of mortality of non-HIV pneumocystis pneumonia.","volume":"79","author":"Inoue","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13613-020-00649-9","article-title":"Adjunctive corticosteroids may be associated with better outcome for non-HIV pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies.","volume":"10","author":"Ding","year":"2020","journal-title":"Ann Intensive Care"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1465-9921-14-87","article-title":"Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia.","volume":"14","author":"Lemiale","year":"2013","journal-title":"Respir Res"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/23744235.2016.1225980","article-title":"High pneumocystis jirovecii colonization rate among haemodialysis patients.","volume":"49","author":"Fritzsche","year":"2017","journal-title":"Infect Dis (Lond)"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","article-title":"Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome.","volume":"50","author":"Mekinian","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/eci.12410","article-title":"Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.","volume":"45","author":"Kronbichler","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","article-title":"Risk factors and clinical characteristics of pneumocystis jirovecii pneumonia in lung cancer.","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s10096-021-04227-0","article-title":"Characteristics and risk factors for pneumocystis jirovecii pneumonia in patients with idiopathic membranous nephropathy.","volume":"40","author":"Yang","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1093\/rheumatology\/keab941","article-title":"Characterization and associated risk factors of pneumocystis jirovecii pneumonia in patients with AIRD: a retrospective study.","volume":"61","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0306-4530(96)00021-2","article-title":"Immune regulation in cushing\u2019s syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones.","volume":"21","author":"Kronfol","year":"1996","journal-title":"Psychoneuroendocrinology"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids.","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:36:56Z","timestamp":1746326216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033351","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}